- Conditions
- Intermittent Claudication
- Interventions
- Cilostazol
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Intermittent Claudication
- Interventions
- Cilostazol
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Intermittent Claudication
- Interventions
- Cilostazol 100 mg, PMR 150 mg, PMR 200 mg
- Drug
- Lead sponsor
- Genovate Biotechnology Co., Ltd.,
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Multiple Sclerosis
- Interventions
- Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Contraception
- Interventions
- Cilostazol
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 33 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Intermittent Claudication
- Interventions
- K-134, Cilostazol 100 mg BID, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
- Conditions
- Raynaud's Disease
- Interventions
- Pletal
- Drug
- Lead sponsor
- Otsuka America Pharmaceutical
- Industry
- Eligibility
- 5 Years to 16 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 19
- States / cities
- Anchorage, Alaska • Fresno, California • Madera, California + 16 more
- Conditions
- Healthy
- Interventions
- Cilostazol 100 mg tablets, Pletal® 100 mg tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
- Interventions
- Cilostazol 100 mg, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Peripheral Arterial Disease, Claudication
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 12
- States / cities
- Bellevue, Washington • Bellingham, Washington • Everett, Washington + 6 more
- Conditions
- Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
- Interventions
- Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment
- Other · Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Intermittent Claudication
- Interventions
- Cilostazol 100 mg, PMR 200 mg
- Drug
- Lead sponsor
- Genovate Biotechnology Co., Ltd.,
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Peripheral Arterial Disease, Claudication (Finding)
- Interventions
- Cilostazol
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Intermittent Claudication
- Interventions
- Cilostazol 100 mg, PMR 135 mg
- Drug
- Lead sponsor
- Genovate Biotechnology Co., Ltd.,
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Peripheral Artery Disease
- Interventions
- Pentoxifylline, Cilostazol
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 10,398 participants
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stroke
- Interventions
- Telmisartan, Metformin, Cilostazol
- Drug
- Lead sponsor
- Spaulding Rehabilitation Hospital
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Intermittent Claudication
- Interventions
- Cilostazol Tablet 100 mg, PMR Tablet 135 mg
- Drug
- Lead sponsor
- Genovate Biotechnology Co., Ltd.,
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
- Interventions
- Levocarnitine tartrate, cilostazol
- Dietary Supplement · Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Cilostazol 100Mg Tab, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease
- Interventions
- Cilostazol
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Healthy
- Interventions
- Cilostazol Tablets 100 mg, Pletal® Tablets 100 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Cardiovascular Diseases, Peripheral Vascular Diseases, Atherosclerosis
- Interventions
- Stent, Supervised Exercise Therapy, Cilostazol
- Device · Behavioral · Drug
- Lead sponsor
- Joselyn Cerezo, MD
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 26
- States / cities
- Loma Linda, California • Orange, California • Palo Alto, California + 23 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Cilostazol 100 MG, Placebo
- Drug · Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Southfield, Michigan
- Conditions
- Intermittent Claudication
- Interventions
- SL650472, Clopidogrel
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey